{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1029","value":"3253"},{"groupId":"OG001","spread":"984","value":"3145"},{"groupId":"OG002","spread":"803","value":"2392"},{"groupId":"OG003","spread":"1143","value":"2994"},{"groupId":"OG004","spread":"804","value":"2617"},{"groupId":"OG005","spread":"838","value":"2886"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"93"},{"groupId":"OG003","value":"104"},{"groupId":"OG004","value":"100"},{"groupId":"OG005","value":"100"}],"units":"Participants"}],"description":"Blood samples were collected at pre-specified timepoints to determine the AUCss in participants receiving Lenvatinib (Lenva) co-administered with Pembrolizumab (Pembro). AUCss was defined as a measure of drug exposure that was calculated as the product of plasma drug concentration and time after drug administration at steady state. AUCss determined by blood samples collected pre-dose and at designated timepoints post-dose are presented. Noncompartmental analysis was used to calculate AUC0ss for each participant. Mean and standard deviation of AUCss were calculated for each cohort. As specified in the protocol, pharmacokinetic analysis was not planned or conducted in Cohorts D2 and G.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenvatinib (lenva) 20 mg via oral capsule once a day (QD) up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG000","title":"Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG001","title":"Cohort B: Ovarian Cancer (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG002","title":"Cohort C: Gastric Cancer (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG003","title":"Cohort D1: Colorectal Cancer (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG004","title":"Cohort E: Glioblastoma Multiforma (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG005","title":"Cohort F: Biliary Tract Cancer (Lenva + Pembro)"}],"paramType":"MEAN","populationDescription":"All allocated participants who received at least 1 dose of study intervention and had data available for this endpoint.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose and 2-12 hours post-dose; Cycle 2 Day 1: pre-dose, 0.5-4 hours, and 6-10 hours post-dose (up to approximately 23 days). Each cycle is 21 days.","title":"Area Under the Concentration Curve at Steady State (AUCss) of Lenvatinib","type":"SECONDARY","unitOfMeasure":"ng*hr/mL"}